Navigation Links
Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Date:2/11/2008

Company Also Provides Update on DARA Program's Ongoing Phase 2a

Hypertension Study

PRINCETON, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the nomination of PS031291 as a preclinical development compound from its internal CCR1 discovery program. PS031291 is a potent and highly selective antagonist at the chemokine receptor CCR1, which has been implicated to play a significant role in multiple inflammatory and autoimmune disease processes. Pharmacopeia believes PS031291 may possess significant potential in the oral treatment of multiple myeloma and various inflammatory diseases including rheumatoid arthritis. The company intends to initiate GLP toxicology studies on the compound in the current quarter.

"PS031291 strengthens Pharmacopeia's internal pipeline with a wholly-owned development candidate with the potential to address significant therapeutic needs," said Les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "We believe this nomination is a testament to our drug discovery expertise which has already generated a number of clinical compounds for our strategic partners."

While a number of compounds discovered by Pharmacopeia are being developed by its various collaborators, PS031291 is the first compound to emerge from Pharmacopeia's internal drug discovery efforts into its internal development portfolio. Pharmacopeia's internal clinical pipeline consists of PS433540 (DARA) for hypertension and diabetic nephropathy and PS178990 (SARM) for muscle wasting associated with a number of serious medical conditions including end-stage renal disease
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
2. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Announces Third Quarter 2007 Financial Results
4. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
7. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
11. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... SANTA ROSA, Calif. , Oct. 24, 2014 /PRNewswire-USNewswire/ ... he was ordering large quantities of multiple controlled substances, ... patient care. They also reported that Dr. Gurney was ... Medical Board reported that one of his employees said ... his care and treatment of patients." Dr. ...
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today that the ... company permission to conduct an open-label study of Antineoplastons ... age with a diffuse intrinsic brainstem glioma (DIPG). Study ... groups based on their age and whether or not ... study endpoint is a decrease in the size of ...
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
Breaking Medicine Technology:Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3
... , Inc., a full-service contract research organization (CRO), and ... combat the growing issue of antibiotic resistance, have partnered ... walk to benefit the Cystic Fibrosis (CF) Foundation through ... Aptalis Pharma) are also working together on clinical trials ...
... May 2, 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... March 31, 2012.  For the first quarter of 2012, the ... per share, compared with a net income of $2.9 million, ... 2011. This $3.8 million change in operating results is primarily ...
Cached Medicine Technology:Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6
(Date:10/25/2014)... shorter, darker days can trigger a type of depression, ... People affected by seasonal affective disorder, also ... even have trouble getting out of bed. In extreme ... Halaris, a professor in the department of psychiatry and ... Medicine. "Seasonal affective disorder should not be taken ...
(Date:10/22/2014)... October 22, 2014 On Saturday, October 25, ... fourth annual family health and fitness fair ¡Vive tu vida! ... activity and good nutrition for better health and wellness for ... is free and open to the public, will be held ... from 9:00 am to 1:00 pm. , “¡Vive tu ...
(Date:10/22/2014)... Medical Solutions , the nation’s ... announce that our co-founder and CFO, Scott Anderson, ... 100 for 2014. Anderson was also named to ... in the staffing industry,” in 2013.     , Under ... staffing company in the U.S., was named a ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
Breaking Medicine News(10 mins):Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3
... better control of disease when chemo is targeted to specific ... The number one cancer killer, lung cancer, may be more ... tumors with key genetic traits, a new study finds. , ... that, overall, 46 percent of patients with stage IV (advanced) ...
... from a sentinel lymph node removed during surgery is a ... false negatives, which means the node, when analyzed under a ... occur in the patient. The sentinel node is the first ... Now, researchers from Georgetown Lombardi Comprehensive Center say that they ...
... ... a Build-a-Beam interactive feature, Keilhauer,s new microsite for Beam Seating makes specifying beam seating ... ... and Simple Beam seating expand the original series to such an extent it can ...
... ... restrictions, and more severe problems, like sleep apnea, can increase the risk of heart attack ... Denver, ... are diagnosed with sinusitis, and many of these people find long-term relief and a new ...
... ... ... 18, 2010 -- Allegheny Medical Integrated Health Services ( http://www.alleghenymedical.com/ ), one of Pittsburgh,s ... mission is to build better health for every aspect of an individual,s life. ...
... ... Touchstone Products LLC is proud to announce the unveiling of its ... affordable prices directly to the American Consumer. TouchstoneSaunas.com offers premium ... your home. Constructed from the highest quality materials to provide ...
Cached Medicine News:Health News:Matching Tumor Types to Drugs Boosts Lung Cancer Outcomes 2Health News:Matching Tumor Types to Drugs Boosts Lung Cancer Outcomes 3Health News:Routine breast cancer biopsy might predict lymph node cancer spread 2Health News:Keilhauer's Expanded Beam Seating Launches With its Own Microsite 2Health News:Keilhauer's Expanded Beam Seating Launches With its Own Microsite 3Health News:Breathing Obstructions Caused by Sinusitis can Require Surgery, says Denver's Nose Doc 2Health News:Breathing Obstructions Caused by Sinusitis can Require Surgery, says Denver's Nose Doc 3Health News:Allegheny Medical's Occupational Health Services Helps Employers Build a Healthier Workforce 2Health News:Allegheny Medical's Occupational Health Services Helps Employers Build a Healthier Workforce 3Health News:Touchstone Saunas Goes Online to Provide Premium Quality Infrared Saunas 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: